Examining bile acids and microbiome changes in early colorectal cancer development
Bile Acids and Microbiome - Possible Novel Progression Factors and Diagnostic Indicators in Early Colorectal Carcinogenesis
This study is trying to see how changes in bile acids and gut bacteria might affect the development of colorectal cancer in adults who have polyps or cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Vilnius University Academic / other |
| Locations | 1 site (Vilnius) |
| Trial ID | NCT06502704 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between bile acid metabolism and microbiome composition in patients with colorectal neoplasms, including small and large adenomas and invasive colorectal cancer. The study aims to understand how these changes may contribute to the progression from adenoma to carcinoma. Adult participants referred for colonoscopy will provide fecal samples for analysis, alongside healthy controls, to identify potential biomarkers associated with colorectal cancer development.
Who should consider this trial
Good fit: Ideal candidates include adults with clinical indications for colonoscopy who have been diagnosed with small or large adenomas or invasive colorectal cancer.
Not a fit: Patients who are pregnant, immunocompromised, or have a history of colorectal diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and early detection strategies for colorectal cancer.
How similar studies have performed: While the relationship between bile acids, microbiome, and colorectal cancer is being explored, this specific approach is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Patients that have clinical indications for colonoscopy Exclusion Criteria: * Pregnancy * Immunocompromised * Previously diagnosed colorectal diseases * Radiotherapy to the pelvis * Long term antibiotic use within 6 months * Continuous use of proton pump inhibitors
Where this trial is running
Vilnius
- Vilnius University Hospital Santaros Klinikos — Vilnius, Lithuania (Recruiting)
Study contacts
- Principal investigator: Tomas Poskus, PhD — Vilnius University
- Study coordinator: Tomas Poskus, PhD
- Email: Tomas.Poskus@santa.lt
- Phone: +37052365000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.